Skip to main content

Table 2 MYC, FBXW7 and TP53 mRNA expression levels and clinicopathological factors of 33 gastric cancer patients

From: MYC, FBXW7 and TP53 copy number variation and expression in Gastric Cancer

 

n (%)

MYC

p- value

FBXW7

p- value

TP53

p- value

  

Median ± IQR

 

Median ± IQR

 

Median ± IQR

 

Age (y) (mean ± SD)

       

>50 (65.3 ± 9.1)

19 (57.6%)

2.04 ± 1.35

0.8873

0.55 ± 0.37

0.9247

0.86 ± 0.62

0.7409

≤50 (42.1 ± 8.2)

14 (42.4%)

1.44 ± 4.88

 

0.53 ± 0.50

 

0.94 ± 1.65

 

Gender

       

Male

15 (45.5%)

2.01 ± 1.01

0.4065

0.53 ± 0.22

0.6353

0.89 ± 0.58

0.8125

Female

18 (54.5%)

1.67 ± 2.03

 

0.56 ± 0.56

 

0.87 ± 0.69

 

Histopathology

       

Intestinal

22 (66.7%)

2.06 ± 0.99

0.3525

0.53 ± 0.16

0.1391

0.81 ±0.78

0.3311

Diffuse

11 (33.3%)

1.40 ± 2.32

 

0.77 ±0.74

 

0.94 ± 0.38

 

Depth of tumor invasion

       

T1

6 (18.2%)

0.89 ± 0.47

0.0857

0.88 ± 0.58

0.0678

0.85 ± 0.15

0.7069

T2-T4

27 (81.8%)

2.08 ± 1.42

 

0.53 ± 0.43

 

0.91 ± 0.79

 

Lymph node metastasis

       

Absent

13 (39.4%)

0.98 ± 1.09

0.0225*

0.68 ± 0.36

0.0238*

0.84 ± 0.44

0.6121

Present

20 (60.6%)

2.10 ± 2.20

 

0.46 ± 0.38

 

0.94 ± 0.79

 

Stage

       

I-II

18 (54.5%)

1.39 ± 1.23

0.0362*

0.57 ± 0.38

0.0380*

0.83 ± 0.55

0.0892

III-IV

15 (45.5%)

2.41 ± 2.79

 

0.34 ± 0.45

 

0.96 ± 1.19

 

MYC IHC

       

Positive

20 (60.6%)

2.18 ± 1.59

0.0022*

0.53 ± 0.32

0.4090

0.81 ± 0.57

0.1372

Negative

13 (39.4%)

0.89 ± 0.85

 

0.58 ± 0.53

 

0.99 ± 0.90

 

p53 IHC

       

Positive

7 (21.2%)

4.25 ± 6.53

0.0891

0.64 ± 0.68

0.9203

1.06 ± 0.83

0.2937

Negative

26 (78.8%)

2.00 ± 1.44

 

0.55 ± 0.35

 

0.87 ± 0.60

 
  1. *p < 0.05; IQR: interquartile range.